P2RX7 and cancer: Since the development of these new drugs, pharmacological inhibition of P2RX7 has proven to be effective and well-tolerated treatment in multiple rodent models of inflammatory diseases including neurological, musculoskeletal as well as retinal, kidney, bladder, liver, lung, and skin-based inflammatory disorders (reviewed extensively in Bartlett et al., 2014, in models of stroke, brain trauma, hemorrhage and also in BBB integrity loss Zhao et al., 2016) as well as muscular dystrophy, cardiomyopathy, respiratory disorders, inflammatory bowel disease and cancer.